TeraImmune
Company

Last deal

$2.96M

Amount

Debt Financing

Stage

22.12.2022

Date

2

all rounds

$2.96M

Total amount

date founded

Financing round

General

About Company
TeraImmune develops cell therapeutics for autoimmune diseases and immune-related disorders.

Industry

Sector :

Subsector :

founded date

01.09.2016

Number of employees

Company Type

For Profit

Last funding type

Debt Financing

IPO status

Private

Description

The company uses regulatory T (Treg) cells from a donor to create Treg cells for hemophilia, multiple sclerosis, and graft-versus-host disease from stem cell transplantation. This enables the healthcare industry to suppress unwanted immune reactions without side effects in patients with autoimmune diseases. Founded in 2016 and based in Germantown, Maryland, TeraImmune was acquired by Baudax Bio in June 2023, although the terms of the transaction were not disclosed.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Abata Therapeutics

Abata Therapeutics

Abata Therapeutics develops cell therapy to treat autoimmune and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

2

total raised

$95M
Mozart Therapeutics

Mozart Therapeutics

Mozart Therapeutics develops CD8 T cell immune modulators for autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

total rounds

2

total raised

$80M
Sonoma BioTherapeutics

Sonoma BioTherapeutics

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

South San Francisco, CA, USA

total rounds

5

total raised

$410M
Checkmab

Checkmab

CheckmAb develops monoclonal antibodies against Treg cells in diseased tissues for autoimmune disease immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Milan, Metropolitan City of Milan, Italy
M&A Details
1

Transaction name

Acquired by

Baudax Bio

announced date

30.06.2023

Financials

Funding Rounds
2
2

Number of Funding Rounds

$2.96M

Money Raised

Their latest funding was raised on 22.12.2022. Their latest round Debt Financing

Date 
Funding Round 
Investors 
Money Raised 
Lead 
22.12.2022
$2.96M
01.01.2020
1
Co-Investors
Investors
1
0

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
No
Venture - Series Unknown
Shinhan Venture Investment

Shinhan Venture Investment

Shinhan Venture Investment is an investment company that specializes in early-stage and later-stage investments.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Seoul, South Korea

count Of Investments

276

count Of Exists

2

People

Employee Profiles
3
Dennis Hahm

Dennis Hahm

Business Development Director

Jay Park

Jay Park

Co-Founder and Chief Operating Officer

Yong Chan Kim

Yong Chan Kim

Founder and Chief Executive Officer

Activity

Recent News
0